Case report shows metabolic improvement after changing to bevacizumab in patients with immunotherapy resistance in malignant pleural mesothelioma, suggesting new treatment strategies.
Malignant mesothelioma is a rare but highly aggressive malignancy associated with a poor prognosis. Similar to many other solid tumors, cytotoxic chemotherapy has traditionally been the standard treatment for patients with locally advanced or metastatic malignant pleural mesothelioma (MPM). However, with increasing recognition of immune dysregulation, immune-directed therapies have assumed a growing role in the management of mesothelioma. Here, we report a case of epithelioid-type malignant pleural mesothelioma that demonstrated primary resistance to ipilimumab plus nivolumab, followed by a marked metabolic response on 18F-FDG PET/CT after switching to bevacizumab plus pemetrexed plus carboplatin.
No takes yet. Share an insight, caveat, or question.
Öksüzoğlu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: